Ozempic subcutaneous injection 1.0 mg SD (YJ code: 2499418G3020, standard: 1mg 0.5mL 1 kit), manufactured by Novo Nordisk Pharma, contains semaglutide (genetical recombination). This once-weekly GLP-1 receptor agonist improves glycemic control in adults with type 2 diabetes and reduces the risk of major cardiovascular events in those with established cardiovascular disease.
Ozempic subcutaneous injection 1.0 mg SD
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →